Cargando…

Comparison of Segmentation Methods in Assessing Background Parenchymal Enhancement as a Biomarker for Response to Neoadjuvant Therapy

Breast parenchymal enhancement (BPE) has shown association with breast cancer risk and response to neoadjuvant treatment. However, BPE quantification is challenging, and there is no standardized segmentation method for measurement. We investigated the use of a fully automated breast fibroglandular t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nguyen, Alex Anh-Tu, Arasu, Vignesh A., Strand, Fredrik, Li, Wen, Onishi, Natsuko, Gibbs, Jessica, Jones, Ella F., Joe, Bonnie N., Esserman, Laura J., Newitt, David C., Hylton, Nola M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Grapho Publications, LLC 2020
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7289261/ https://www.ncbi.nlm.nih.gov/pubmed/32548286 http://dx.doi.org/10.18383/j.tom.2020.00009

Ejemplares similares

Tumor Sphericity Predicts Response in Neoadjuvant Chemotherapy for Invasive Breast Cancer
por: Li, Wen, et al.
Publicado: (2020)

Impact of MRI Protocol Adherence on Prediction of Pathological Complete Response in the I-SPY 2 Neoadjuvant Breast Cancer Trial
por: Onishi, Natsuko, et al.
Publicado: (2020)

Post-Processing Bias Field Inhomogeneity Correction for Assessing Background Parenchymal Enhancement on Breast MRI as a Quantitative Marker of Treatment Response
por: Nguyen, Alex Anh-Tu, et al.
Publicado: (2022)

Effect of MR Imaging Contrast Thresholds on Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Subtypes: A Subgroup Analysis of the ACRIN 6657/I-SPY 1 TRIAL
por: Li, Wen, et al.
Publicado: (2016)

Effect of Imaging Parameter Thresholds on MRI Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Subtypes
por: Lo, Wei-Ching, et al.
Publicado: (2016)

Diffusion-Weighted MRI for Predicting Pathologic Complete Response in Neoadjuvant Immunotherapy
por: Li, Wen, et al.
Publicado: (2022)

Effect of Inter-Reader Variability on Diffusion-Weighted MRI Apparent Diffusion Coefficient Measurements and Prediction of Pathologic Complete Response for Breast Cancer
por: Le, Nu N., et al.
Publicado: (2022)

MRI Enhancement in Stromal Tissue Surrounding Breast Tumors: Association with Recurrence Free Survival following Neoadjuvant Chemotherapy
por: Jones, Ella F., et al.
Publicado: (2013)

Current Landscape of Breast Cancer Imaging and Potential Quantitative Imaging Markers of Response in ER-Positive Breast Cancers Treated with Neoadjuvant Therapy
por: Jones, Ella F., et al.
Publicado: (2020)

Features of MRI stromal enhancement with neoadjuvant chemotherapy: a subgroup analysis of the ACRIN 6657/I-SPY TRIAL
por: Olshen, Adam, et al.
Publicado: (2017)

Diffusion Tensor Imaging for Assessment of Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer
por: Wilmes, Lisa J., et al.
Publicado: (2016)

Circulating tumor DNA and magnetic resonance imaging to predict neoadjuvant chemotherapy response and recurrence risk
por: Magbanua, Mark Jesus M., et al.
Publicado: (2021)

Quantitative background parenchymal enhancement to predict recurrence after neoadjuvant chemotherapy for breast cancer
por: Moliere, Sebastien, et al.
Publicado: (2019)

Radiomic tumor phenotypes augment molecular profiling in predicting recurrence free survival after breast neoadjuvant chemotherapy
por: Chitalia, Rhea, et al.
Publicado: (2023)

The association between breast cancer risk factors and background parenchymal enhancement at dynamic contrast-enhanced breast MRI
por: Hellgren, Roxanna, et al.
Publicado: (2020)

Predicting breast cancer response to neoadjuvant treatment using multi-feature MRI: results from the I-SPY 2 TRIAL
por: Li, Wen, et al.
Publicado: (2020)

Prediction of Treatment Response to Neoadjuvant Chemotherapy for Breast Cancer via Early Changes in Tumor Heterogeneity Captured by DCE-MRI Registration
por: Jahani, Nariman, et al.
Publicado: (2019)

Association Between Background Parenchymal Enhancement and Pathologic Complete Remission Throughout the Neoadjuvant Chemotherapy in Breast Cancer Patients
por: You, Chao, et al.
Publicado: (2017)

Background parenchymal enhancement: behavior during neoadjuvant chemotherapy for breast cancer and relationship with a pathological complete response
por: Teixeira, Sandra Regina Campos, et al.
Publicado: (2020)

Response Predictivity to Neoadjuvant Therapies in Breast Cancer: A Qualitative Analysis of Background Parenchymal Enhancement in DCE-MRI
por: La Forgia, Daniele, et al.
Publicado: (2021)

Background parenchymal enhancement in preoperative breast MRI
por: Kohara, Satoko, et al.
Publicado: (2015)

Impact of deformable registration methods for prediction of recurrence free survival response to neoadjuvant chemotherapy in breast cancer: Results from the ISPY 1/ACRIN 6657 trial
por: Thakran, Snekha, et al.
Publicado: (2022)

Analysis of background parenchymal echogenicity on breast ultrasound: Correlation with mammographic breast density and background parenchymal enhancement on magnetic resonance imaging
por: Ko, Kyung Hee, et al.
Publicado: (2017)

Evaluation of primary breast cancers using dedicated breast PET and whole-body PET
por: Hathi, Deep K., et al.
Publicado: (2020)

Generalizable attention U-Net for segmentation of fibroglandular tissue and background parenchymal enhancement in breast DCE-MRI
por: Nowakowska, Sylwia, et al.
Publicado: (2023)

Background Parenchymal Enhancement of the Contralateral Normal Breast: Association with Tumor Response in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy()
por: Chen, Jeon Hor, et al.
Publicado: (2015)

Exploration of PET and MRI radiomic features for decoding breast cancer phenotypes and prognosis
por: Huang, Shih-ying, et al.
Publicado: (2018)

MRI Texture Analysis of Background Parenchymal Enhancement of the Breast
por: Amano, Yasuo, et al.
Publicado: (2017)

MRI Background Parenchymal Enhancement Is Not Associated with Breast Cancer
por: Bennani-Baiti, Barbara, et al.
Publicado: (2016)

Accuracy of breast MRI in evaluating nodal status after neoadjuvant therapy in invasive lobular carcinoma
por: Abel, Mary Kathryn, et al.
Publicado: (2021)

Prophylactic breast irradiation reduces background parenchymal enhancement (BPE) on MRI: A secondary analysis()
por: Ben-David, Merav A., et al.
Publicado: (2019)

Correction: MRI Background Parenchymal Enhancement Is Not Associated with Breast Cancer
por: Bennani-Baiti, Barbara, et al.
Publicado: (2016)

Background Parenchymal Enhancement on Preoperative Magnetic Resonance Imaging: Association With Recurrence-Free Survival in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy
por: Choi, Ji Soo, et al.
Publicado: (2016)

Changes in background parenchymal enhancement in HER2-positive breast cancer before and after neoadjuvant chemotherapy: Association with pathologic complete response
por: Dong, Jing-Min, et al.
Publicado: (2018)

Initial experience of dedicated breast PET imaging of ER+ breast cancers using [F-18]fluoroestradiol
por: Jones, Ella F., et al.
Publicado: (2019)

Background Parenchymal Enhancement on Breast MRI as a Prognostic Surrogate: Correlation With Breast Cancer Oncotype Dx Score
por: Zhang, Michelle, et al.
Publicado: (2021)

A Review on Automatic Mammographic Density and Parenchymal Segmentation
por: He, Wenda, et al.
Publicado: (2015)

MRI background parenchymal enhancement, breast density and serum hormones in postmenopausal women
por: Brooks, Jennifer D., et al.
Publicado: (2018)

Clinically Meaningful Tumor Reduction Rates Vary by Prechemotherapy MRI Phenotype and Tumor Subtype in the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)
por: Mukhtar, Rita A., et al.
Publicado: (2013)

Association of breast cancer with MRI background parenchymal enhancement: the IMAGINE case-control study
por: Watt, Gordon P., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_vd37qaj7mk70qt4eqjm4abmjc2